This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
and Vertex' Incivek (telaprevir).
its toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Dion added: “ This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some ... Merck &Co. III. paritaprevir.
More from news
Approximately 2 fully matching, plus 47 partially matching documents found.
172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...